Sage Therapeutics is a biopharmaceutical company developing novel therapies for brain health disorders with Depression, Neurology and Neuropsychiatric franchise programs.

Sage Therapeutics is a biopharmaceutical company developing novel therapies for brain health disorders with Depression, Neurology and Neuropsychiatric franchise programs.

CAMBRIDGE, Mass., January 12, 2025 -- (BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s strategic...

Find the latest Sage Therapeutics, Inc. (SAGE) stock quote, history, news and other vital information to help you with your stock trading and investing.

Jan 28, 2025 · The offer price represented a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Jan. 10. Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the company.

Jan 27, 2025 · Sage Therapeutics Inc. is looking for a deal — but it’s not interested in the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.. The Cambridge ...

4 days ago · Get a real-time Sage Therapeutics, Inc. (SAGE) stock price quote with breaking news, financials, statistics, charts and more.

Nov 20, 2024 · Sage Therapeutics said on Wednesday it would stop the development of its experimental drug following the latest failure in a study testing it in patients with Huntington's disease, a rare...

Oct 17, 2024 · Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain ...

Feb 6, 2023 · Zuranolone (SAGE-217/BIIB125) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM).